Meeting
2020 ASCO Virtual Scientific Program
GEN-009, a neoantigen vaccine containing ATLAS selected neoantigens, to generate broad sustained immunity against immunogenic tumor mutations and avoid inhibitory peptides.
Authors
Roger B. Cohen
University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
Roger B. Cohen , Przemyslaw Twardowski , Melissa Lynne Johnson , Maura L. Gillison , Mark N. Stein , Ulka N. Vaishampayan , Lisa McNeil , Mara Shainheit , Daniel DeOliveira , Manish Jain , Jessica Price , Richard Hernandez , Arthur P. DeCillis , Narinderjeet Singh , Jessica Flechtner , Thomas A. Davis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
New Targets and New Technologies (IO)
Clinical Trial Registration Number
NCT03633110
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3107)
DOI
10.1200/JCO.2020.38.15_suppl.3107
Abstract #
3107
Poster Bd #
171
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase 1/2a study of GEN-009, a neoantigen vaccine based on autologous peptide immune responses.
First Author: Roger B. Cohen
Poster
2021 ASCO Annual Meeting
Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.
First Author: Maura L. Gillison
Poster
2021 ASCO Annual Meeting
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.
First Author: Mark Yarchoan
Poster
2018 ASCO Annual Meeting
A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission.
First Author: Roisin Eilish O'Cearbhaill